Venrock Healthcare trims KalVista stake in $3.69M sale as Ekterly sales draw analyst attention
Venrock Healthcare Capital Partners III and affiliated entities sold roughly $3.69 million of KalVista Pharmaceuticals (NASDAQ: KALV) stock across transactions on March 25 and March 26, 2026. The disposals were executed at prices between $16.95 and $19.12 per share. After the sales the group retains 5,089,354 shares. The stock is trading near its 5…